# Zenflow

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zenflow

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.zenflow.com
- Total disclosed funding: $116M
- Latest round: Series D (Oct 5, 2026)
- Investors on record: 15

## About

Zenflow, Inc. is a US-based innovator focused on providing a minimally invasive treatment for benign prostatic hyperplasia (BPH), offering patients a comfortable and effective alternative to traditional procedures.Founded in 2014 and headquartered in San Francisco, US, Zenflow, Inc. specializes in treatments for benign prostatic hyperplasia (BPH). The company was founded by Shreya Mehta, who has a history in medical innovation. In October 2026, Zenflow, Inc. raised an undisclosed amount of venture debt funding from Hsbc Bank Usa, National Association and Trinity Capital. Zenflow is dedicated to treating benign prostatic hyperplasia (BPH), which affects many men over 50. Their core offering is a minimally invasive procedure that relieves BPH symptoms without the need for cutting or piercing tissue. This innovative treatment, developed in collaboration with leading urologists through the Stanford Byers Center for Biodesign, emphasizes comfort and rapid recovery, targeting adult males seeking effective solutions. The company focuses on regions with high BPH prevalence, particularly in North America and Europe.Zenflow generates revenue from its unique BPH treatment procedure, offered through partnerships with healthcare providers and urologists. This model allows patients to access the procedure through their doctors, who often recommend Zenflow's solution for symptom relief. While specific pricing details are not disclosed, the revenue model is structured around fees for the procedure and any necessary follow-up care, aiming to establish a consistent revenue stream by addressing the needs of men experiencing BPH.

The company will use the October 2026 funding to bring the Zenflow Spring® System to market following its U.S. FDA premarket approval.

## Funding rounds

- Series D, Oct 5, 2026, $52M — F-Prime Capital, Invus Financial Advisors, Medical Technology Venture Partners, COOK MEDICAL LLC, ClavystBio
- Series C, Nov 1, 2024, $24M — Invus [DUP], F-Prime Capital, Medical Technology Venture Partners, COOK MEDICAL LLC
- Series B, Apr 9, 2021, $24M — Invus [DUP], F-Prime Capital, Golden Seeds, Astia Angels, SV Tech Ventures, Medical Technology Venture Partners, Cloudstone Venture
- Series A, Sep 12, 2017, $11M — F-Prime Capital, Invus Financial Advisors, Medical Technology Venture Partners
- Seed, May 1, 2017, $5.2M — Y Combinator, Dorm Room Fund, Astia Angels, StartX, Varsity, NewDo Venture

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Dorm Room Fund (https://capitalatlas.ai/funds/dorm-room-fund) — Seed
- Astia Angels (https://capitalatlas.ai/funds/astia-angels) — Seed, Series B
- StartX — Seed
- Varsity (https://capitalatlas.ai/funds/varsity) — Seed
- NewDo Venture (https://capitalatlas.ai/funds/newdo-venture) — Seed
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B, Series C, Series D
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series A, Series D
- Medical Technology Venture Partners (https://capitalatlas.ai/funds/medical-technology-venture-partners) — Series A, Series B, Series C, Series D
- Invus [DUP] — Series B, Series C
- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Series B
- SV Tech Ventures (https://capitalatlas.ai/funds/sv-tech-ventures) — Series B
- Cloudstone Venture (https://capitalatlas.ai/funds/cloudstone-venture) — Series B
- COOK MEDICAL LLC — Series C, Series D
- ClavystBio (https://capitalatlas.ai/funds/clavystbio) — Series D